{"id":53749,"date":"2025-04-24T08:00:00","date_gmt":"2025-04-24T06:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-interim-report-q1-2025\/"},"modified":"2025-04-27T18:08:21","modified_gmt":"2025-04-27T16:08:21","slug":"stille-ab-interim-report-q1-2025","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-interim-report-q1-2025\/","title":{"rendered":"Stille AB: Interim Report Q1 2025"},"content":{"rendered":"
\n

Stille AB (publ) today presents the report for the first quarter 2025.<\/strong><\/p>\n<\/div>\n

\n

Revenue amounted to 129.3 MSEK (139.7) impacted by temporary delivery restrictions and the phase-out of non-strategic products.<\/p>\n

\u201cStille starts 2025 with a quarter marked by temporary challenges.\u201d <\/em>says Torbj\u00f6rn Sk\u00f6ld but also points out,\u201cOrder intake<\/em>
remained strong, in line with financial targets, providing good conditions for recovery and growth during the rest of the year\u201d<\/em><\/p>\n

The gross profit amounted to 51.1 percent (48.6) and EBIT before one-time costs amounted to 17.9 MSEK (27.0).<\/p>\n

\u201d<\/em> In June 2025, I will step down as CEO. The Board is currently conducting a thorough recruitment process to ensure continuity of leadership and maintain the company\u2019s strategic direction. I leave my role with full confidence in the Stille team, the company\u2019s strategy and the future\u201d, <\/em>concludes Stille\u2019s CEO.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
MSEK<\/strong><\/td>\nJAN-MAR<\/strong>
<\/strong>2025<\/strong><\/td>\n		JAN-MAR<\/strong>
<\/strong>2024<\/strong><\/td>\n		APR-MAR<\/strong>
<\/strong>2024\/2025<\/strong><\/td>\n		JAN-DEC<\/strong>
<\/strong>2024<\/strong><\/td>\n<\/tr>\n
Net sales<\/td>\n129.3\u00a0<\/td>\n139.7\u00a0<\/td>\n559.6\u00a0<\/td>\n569.9\u00a0<\/td>\n<\/tr>\n
Gross profit, %<\/td>\n51.1\u00a0<\/td>\n48.6\u00a0<\/td>\n52.5\u00a0<\/td>\n51.9\u00a0<\/td>\n<\/tr>\n
EBITDA before non-recurring items<\/td>\n25.2\u00a0<\/td>\n33.7\u00a0<\/td>\n134.0\u00a0<\/td>\n142.4\u00a0<\/td>\n<\/tr>\n
EBITDA before non-recurring items, %<\/td>\n19.5\u00a0<\/td>\n24.1\u00a0<\/td>\n23.9\u00a0<\/td>\n25.0\u00a0<\/td>\n<\/tr>\n
EBITDA<\/td>\n25.2\u00a0<\/td>\n17.0\u00a0<\/td>\n106.2\u00a0<\/td>\n98.0\u00a0<\/td>\n<\/tr>\n
EBITDA, %<\/td>\n19.5\u00a0<\/td>\n12.2\u00a0<\/td>\n19.0\u00a0<\/td>\n17.2\u00a0<\/td>\n<\/tr>\n
EBIT before non-recurring items<\/td>\n17.9\u00a0<\/td>\n27.0\u00a0<\/td>\n105.8\u00a0<\/td>\n114.9\u00a0<\/td>\n<\/tr>\n
EBIT before non-recurring items, %<\/td>\n13.8\u00a0<\/td>\n19.3\u00a0<\/td>\n18.9\u00a0<\/td>\n20.2\u00a0<\/td>\n<\/tr>\n
EBIT<\/td>\n17.9\u00a0<\/td>\n10.3\u00a0<\/td>\n78.1\u00a0<\/td>\n70.5\u00a0<\/td>\n<\/tr>\n
EBIT, %<\/td>\n13.8\u00a0<\/td>\n7.4\u00a0<\/td>\n13.9\u00a0<\/td>\n12.4\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Torsh\u00e4lla, April 24th, 2025.<\/p>\n<\/div>\n

\n

This information is information that Stille is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 08:00 CEST.<\/em><\/p>\n<\/div>\n

\n

Contact Details<\/strong>
Torbj\u00f6rn Sk\u00f6ld<\/strong>
CEO & President
+46 (0)70 316 63 91 | torbjorn.skold@stille.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Stille AB (publ) develops, manufactures and markets medical devices<\/strong> for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se<\/a>.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Interim Report Q1 2025<\/a><\/p>\n<\/div>\n